Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Deoxymannojirimycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL13298786 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4619759 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896653 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL142573 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL10028910 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12269503 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2163281 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL13061461 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | claimed |
| EP-2793872-B1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2021-03-10 | — | — | EP | claimed |
| US-20200399675-A1 | DEVICES AND METHODS FOR EXAMINING DRUG EFFECTS ON MICROORGANISMS | ESSENLIX CORPORATION (US) | 2020-12-24 | — | — | US | claimed |
| WO-2019028133-A1 | DEVICES AND METHODS FOR EXAMINING DRUG EFFECTS ON MICROORGANISMS | ESSENLIX CORPORATION (US) | 2019-02-07 | — | — | WO | claimed |
| US-20180193209-A1 | A POLYMER PRODUCT AND PREPARATION THEROF | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2018-07-12 | — | — | US | claimed |
| EP-3319779-A1 | A POLYMER PRODUCT AND PREPARATION THEREOF | Singapore Health Services Pte Ltd (SG) | 2018-05-16 | — | — | EP | claimed |
| CN-108025477-A | Polymer products and their preparation | 新加坡保健服务集团 | 2018-05-11 | — | — | CN | claimed |
| WO-2017117269-A1 | METHODS AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-07-06 | — | — | WO | claimed |
| EP-2793872-A1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | Centogene IP GmbH (DE) | 2014-10-29 | — | — | EP | claimed |
| US-6589964-B2 | Administering a competitive inhibitor of the enzyme in an amount effective to enhance enzyme activtiy, selected from 2,5-dideoxy- 2,5-imino-D-mannitol, 3,4-diepi- alpha -homonojirimycin, 5-O- deoxyglactonojirimycin, calystegines | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-07-08 | — | — | US | claimed |
| US-6583158-B1 | Competitive inhibitors of the enzymes, in particular imino sugars and related compounds | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY | 2003-06-24 | — | — | US | claimed |
| EP-0370205-B1 | Glycosylated polypeptides | KYOWA HAKKO KOGYO KK (JP) | 1998-07-22 | — | — | EP | claimed |
| EP-0353295-B1 | NOVEL AND IMPROVED ANTIBODIES FOR SITE SPECIFIC ATTACHMENT OF COMPOUNDS | CYTOGEN CORP (US) | 1994-04-06 | — | — | EP | claimed |
| EP-0353295-A4 | NOVEL AND IMPROVED ANTIBODIES FOR SITE SPECIFIC ATTACHMENT OF COMPOUNDS. | CYTOGEN CORP (US) | 1990-06-26 | — | — | EP | claimed |
| EP-0370205-A2 | Glycosylated polypeptides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-05-30 | — | — | EP | claimed |
| EP-0353295-A1 | NOVEL AND IMPROVED ANTIBODIES FOR SITE SPECIFIC ATTACHMENT OF COMPOUNDS. | CYTOGEN CORP (US) | 1990-02-07 | — | — | EP | claimed |
| EP-0328508-A2 | Method for synthesis of deoxymannojirimycin | The NutraSweet Company (US) | 1989-08-16 | — | — | EP | claimed |
| WO-1989007114-A1 | NOVEL AND IMPROVED ANTIBODIES FOR SITE SPECIFIC ATTACHMENT OF COMPOUNDS | CYTOGEN CORPORATION (US) | 1989-08-10 | — | — | WO | claimed |
| EP-0318898-A2 | Method for manufacturing 1-deoxymannojirimycin | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1989-06-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | GAA 13/4885GLA 45/4885FUCA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.